Trialbee Extends Executive Team and Launches Partner Program to Accelerate Growth, Expand Global Reach
18.5.2021 15:00:00 CEST | Business Wire | Press Release
Trialbee, a patient matching and enrollment platform, today announces key additions to its leadership team and a strategic partner program to further accelerate the company’s growth. These additions come during a period of unprecedented business results and will further scale the company’s global patient recruitment capabilities for clinical trials.
Trialbee’s emergence as a trusted partner comes at a time when finding qualified patients and simplifying their journey into clinical research is more important than ever. Trialbee Hive™ utilizes real-world data (RWD) and advanced data science to model and expand patient targeting, providing greater awareness, inclusivity, and diversity of relevant patient populations. Interested patients are then engaged through Trialbee’s Candidate Manager platform that incorporates live nurse qualification and telehealth capabilities to refer study-ready patients into the trial, reducing site burden and enhancing enrollment outcomes.
Four of the world’s 10 largest pharmaceutical companies utilize Trialbee to achieve enrollment milestones and provide a patient-centric journey into their global clinical trials. The company has driven strong business momentum over the past year. Revenue in 2020 doubled compared to 2019 and sales in the first quarter of 2021 exceeded 2020 total year sales. Additionally, the company’s global employee base has grown 69% in the past year. Trialbee’s new Partner Program will enable CROs and Decentralized Clinical Trial (DCT) platforms to utilize its technology in their global clinical trials and further scale the business, enabling Trialbee to be included in more global clinical trials. Trialbee is currently engaged in fully global studies in 19 countries with major CROs, large pharmaceutical companies as well as mid-sized biotechs.
Expanded Leadership Team to Drive Success
In addition to adding new strategic partners, Trialbee appointed four new industry veterans to its Executive Leadership team. These include:
- Bill Abbott, VP Sales, US: Mr. Abbott will be leading the growth of Trialbee in the patient recruitment and enrollment space in the United States. With a successful track record at companies like Verana Health and Acurian, Mr. Abbott brings over 30 years of industry experience to Trialbee.
- George Dorsett, VP Sales, Europe: Previously Trialbee’s Sr. Director, Business Development & Customer Solutions, Mr. Dorsett has substantially grown the Trialbee business since joining in 2018; establishing the brand as a leading global player. He has been appointed to VP, Sales to lead Trialbee’s continued success in Europe.
- Vidhi Goel, VP Marketing: Ms. Goel brings over 20 years of strategic marketing experience to Trialbee. With experience gained at AiCure, ERT and Medidata Solutions, Ms. Goel will be focused on Trialbee’s topline growth and brand strength.
- Lauren Sunshine, Sr. Director, Strategic Partnerships: With experience gained at AiCure and Epic, Ms. Sunshine will lead Trialbee’s commitment to being a global patient recruitment innovator by building a partner program with market-leading CROs, Virtual Sites, eClinical and Decentralized Clinical Trial solution providers.
“The industry experience and expertise our leadership team brings demonstrates our commitment to global trials that enable enrollment of diverse candidates, data science-driven enrollment solutions, and trust in our data integrity,” says Trialbee CEO Matt Walz. “We are poised to build on our strong momentum and further establish ourselves as a market leader in Saas-based approaches to patient enrollment.”
In February, Trialbee HIVE™ was released, a smart data science application that uses real world data (RWD) to enhance targeting and precision in performance-driven patient recruitment for global clinical trials. Trialbee HIVE™ uses a smart modeling technique to expand the pool of potential clinical trial participants and then narrows it down to only the most relevant candidates matching the study criteria, accelerating timelines and reducing cost.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with sponsors, CROs, and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005053/en/
Contact information
Media Contact:
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom